M⁶A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer.

ABSTRACT: Small-cell lung cancer (SCLC) is a devastating subtype of lung cancer with few therapeutic options. Despite the advent of immunotherapy, platinum-based chemotherapy is still the irreplaceable first-line therapy for SCLCs. However, drug resistance will invariably occur in most patients and the outcomes are heterogeneous. Therefore, clinically feasible classification strategies and potential therapeutic targets for overcoming chemotherapy resistance are urgently needed. N⁶-methyladenosine (m⁶A) is a novel epigenetic decisive factor that is involved in tumor progression and drug resistance. However, almost nothing is known about m⁶A modification in SCLC. Here, we assessed 200 SCLC samples from patients who underwent chemotherapy from three different cohorts, i

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC8579518 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature